A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

• Status: RECRUITING
• Trial end date: 2028-10-25

Summary

The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)

• Phase: PHASE2

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Carboplatin; Cisplatin; Ipilimumab; Nivolumab; Paclitaxel; Pemetrexed